Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maud Gordat"'
Autor:
Toby M Maher, Michael Kreuter, Vincent Cottin, Susanne Stowasser, Marlies S Wijsenbeek, Yi Liu, Fernando J Martinez, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Maud Gordat, Donald F Zoz
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Methods and analysis In this placebo-controlled, double-blind, phase III trial, patients are being randomised in a 1:1:1 ratio to receive 9 mg or 18 mg of BI 1015550 or placebo two times per day over at least 52 weeks, stratified by use of background
Externí odkaz:
https://doaj.org/article/f2486a20e22e430c8654899f00c91a87
Autor:
Willem Hettema, Stefan Kaspers, Lori M. Laffel, Silke Retlich, Jacques Weill, Dietmar Neubacher, William V. Tamborlane, Maud Gordat, Jan Marquard, Cornelia E Hoesl
Publikováno v:
Pediatric Diabetes. 19:640-648
Objective To identify the dose of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in pediatric patients with type 2 diabetes (T2D). Methods Double-blind, randomized, controlled parallel group study comparing linagliptin 1 and 5 mg once daily
Autor:
Thomas Meinicke, Keizo Kanasaki, Sandra Thiemann, Masakazu Haneda, Per-Henrik Groop, Maud Gordat, Maximilian von Eynatten, Vlado Perkovic, Robert Stanton, Kumar Sharma, Berthold Hocher, Robert D. Toto, Guntram Schernthaner, Jessica Cescutti, Audrey Koitka-Weber, Mark E. Cooper
Publikováno v:
Diabetes, Obesity & Metabolism
Aims The MARLINA-T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard-of-care in individuals with type 2 diabetes and albuminuria. Methods A total of 360 individuals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50205598340e0cc4c30b65b82399945
http://hdl.handle.net/10138/227961
http://hdl.handle.net/10138/227961
Autor:
Masakazu Haneda, Hans-Juergen Woerle, Berthold Hocher, Guntram Schernthaner, Maud Gordat, Per-Henrik Groop, Kumar Sharma, Maximilian von Eynatten, Vlado Perkovic, Jessica Cescutti, Mark E. Cooper
Publikováno v:
Diabetes and Vascular Disease Research. 12:455-462
Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA–T2D™), a multicentre, multinational, randomized, double-blind, placebo-controlled, parallel-group, phase 3b clinical trial, ai